Navigation Links
Sally W. Crawford Joins Insulet's Board of Directors
Date:10/20/2008

ystem and potential adverse changes in reimbursement rates or policies relating to the OmniPod; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; potential termination of Insulet's license to incorporate a blood glucose meter into the OmniPod System; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; adverse regulatory or legal actions relating to the OmniPod System; the potential violation of federal or state laws prohibiting "kickbacks" and false and fraudulent claims or adverse affects of challenges to or investigations into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulet's competitors; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to Insulet's products; Insulet's ability to attract and retain key personnel; Insulet's ability to manage its growth; risks associated with potential future acquisitions; Insulet's ability to maintain compliance with the restrictions and covenants contained in its existing credit and security agreement; Insulet's ability to successfully maintain effective internal controls; and other risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and in the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2008 and its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to
'/>"/>
SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Super Model Cindy Crawford will be Honored at DKMS Linked Against Leukemia Gala on May 7th at Capitale
2. PA Agriculture Department Warns Consumers of Tainted Raw Milk Sold By Clarion, Crawford County Dairies
3. Samplify Systems Adds Computed Tomography Expert Carl Crawford to Technical Team
4. Richard Greco Joins Mediware Board
5. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
6. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
7. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
8. Nick Childs Joins Grey New York as Director of Content Development
9. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
10. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
11. NASN Joins Partnership to Fight Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are meant to ... on the latest weight loss methods by publishing weekly in-depth ... review of Kyle Leon’s Customized Fat Loss Plan ... lose weight or stay in shape with the minimum effort. ... by a popular fitness trainer, Kyle Leon, who has made ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker Waichman ... of victims injured by defective medical devices, is offering remarks ... case of the Estate of Fred E. Taylor v. Intuitive ... Orchard). A May 21, 2013, Bloomberg report noted ... acted like a “car dealership” in how it deployed its ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... One-year results from SOURCE XT one of the ... reported today at EuroPCR 2013 show good clinical ... device success for all access approaches, valve sizes and ... up 2688 consecutively enrolled patients (mean age 81.5 years) ... 93 centres in 17 countries between July 2010 and ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The federal ... hip replacement lawsuits in U.S. District Court, ... response to a request from Plaintiffs’ Counsel to conduct ... The May 17th Order grants that request, and ... conducted. (In re: Wright Medical Technology, Inc., Conserve Hip ...
Breaking Medicine News(10 mins):Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... Based on finding of a recent study researchers say ... day is an effective preventive // measure for people ... anti-epileptic drug. Studies have also shown its success in ... neuralgia, and migraine headache. Since gabapentin often reduces migraines ...
... study reports that kids with asthma are more likely to ... moving or family relationships. // ,60 children who had ... had a history of chronic stress. Over 18 months, kids ... flow tests, which measured their breathing strength. Both kids and ...
... do much to relieve knee pain associated with osteoarthritis, ... studies comparing the drugs to placebos. ,The ... and around 3,000 received placebos. The average age of ... been experiencing symptoms for about eight years. Since long-term ...
... fatigue but can also be dangerous. In some cases ... hours can cause deep-vein thrombosis, a potentially serious condition ... pelvic veins. , ,The risk is greatest for ... cardiovascular disease, cancer and blood-clotting disorders, according to the ...
... could lead to an enlarged heart by early adulthood, ... .// ,Researchers followed 467 children for almost ... participants at childhood with data obtained at young adulthood. ... size. Participants who had the highest BMI levels in ...
... who take high doses of steroids are more than twice ... not, say researchers based on findings of a recent study. ... the skin, lungs, joints, digestive tract, such as asthma, inflammatory ... health records of 68,781 people who used steroids between 1993 ...
Cached Medicine News:
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... to offer synopsis of the current and ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
... May 4 Roche Public Affairs Director Stacy Quinn ... Star by the Healthcare Businesswomen,s Association (HBA) at the organization,s annual awards luncheon ... , , ... for detail and has earned the appreciation and respect of the management team, ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ) first quarter 2010 ... will be broadcast live over the internet on Monday, May 10, 2010 ... , , ... , , ...
Cached Medicine Technology:Roche's Quinn Honored as 2010 HBA Rising Star 2Roche's Quinn Honored as 2010 HBA Rising Star 3DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call 2
Sensitive Eyes drops keep soft contact lenses moist....
Lens Plus Sterile Saline Solution...
... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Sensitive Eyes sterile saline spray is the preservative-free aerosol saline solution for people with eyes sensitive to preservatives. Used for rinsing soft contact lenses after cleaning or thermal or...
Medicine Products: